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1. Introduction
Sudden unexpected death in epilepsy (SUDEP) is the most common disease-related cause of
death in persons with epilepsy. SUDEP includes all epilepsy-related deaths not due to
trauma, drowning, status epilepticus, or other identifiable causes [1]. Evidence from
epidemiologic, observational, clinical, and pathological studies strongly suggests that
SUDEP occurs after generalized tonic-clonic seizures [2].
The physiologic mechanisms underlying SUDEP are poorly understood [2]. However, based
on the literature, several authors have suggested potential strategies to prevent SUDEP: good
seizure control, reduction of stress, participation in physical activity, supervision at night,
seizure monitors that can detect motion or other physiological parameters, and family
training in CPR [2, 3]. Self- and family-management of epilepsy is critical to seizure control.
Therefore, patients and families should be knowledgeable about SUDEP and the importance
of seizure control in potentially preventing SUDEP.
Professional organizations, including the American Epilepsy Society [4], National Institute
for Health and Care Excellence [5], and the Scottish Intercollegiate Guidelines Network [6],
espouse the practice of discussing SUDEP with patients and family members, yet do not
provide clear guidelines in terms of how—or when—these discussions should take place.
© 2013 Elsevier Inc. All rights reserved.
Correspondence to: Wendy R. Miller.
Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our
customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of
the resulting proof before it is published in its final citable form. Please note that during the production process errors may be
discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
NIH Public Access
Author Manuscript
Epilepsy Behav. Author manuscript; available in PMC 2015 March 01.
Published in final edited form as:
Epilepsy Behav. 2014 March ; 32: 38–41. doi:10.1016/j.yebeh.2013.12.020.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Consensus is lacking on how health care practitioners should address SUDEP with patients
and family members, and evidence regarding patient educational interventions is lacking as
well. In general, physicians have employed a physicianled, rather than a patient-centered,
approach to addressing SUDEP with patients. A study examining “truth telling” practices
among Italian epileptologists found that 61.8% of the sample discussed SUDEP with very
few of their patients [7]. Another study explored the effect of talking to patients about
SUDEP. When parents were told about the potential of SUDEP in their children, their initial
distress did not continue. Children in the study were rarely told about SUDEP [7, 8]. An in-
depth investigation into the SUDEP-discussing practices of a variety of practitioners who
commonly provide care to persons with epilepsy is needed. Specifically, uncovering
providers’ reasons for discussing or not discussing SUDEP with patients and family
members is needed to allow for a more informed establishment of SUDEP-discussing
practices.
The purpose of this study was to describe the practices of epileptologists, neurologists, and
advanced practice nurses (APNs) regarding discussing SUDEP with their patients, as well as
to reveal the rationale for their SUDEP-discussing practices; this purpose was fulfilled using
focus group methods and thematic analysis.
2. Methods
2.1. Participant recruitment
The study was approved by the Indiana University Institutional Review Board. Between
December 2011 and September 2012, we recruited adult and pediatric epileptologists,
neurologists, and advanced practice nurses (APNs) at national multi-disciplinary meetings of
neurology or epilepsy providers (American Epilepsy Society and the American Association
of Neuroscience Nurses) to capture the perspective of various epilepsy health care providers.
Invitations to take part in the study were distributed at multiple education venues at these
meetings. Email blasts were also used to alert providers of the opportunity to participate.
Therefore, all registered meeting attendees had the opportunity to participate. Providers
interested in participating in the study contacted the researchers.
2.2. Data collection
All data were collected via focus groups [9], and separate focus groups were held for each of
the three categories of providers. Five separate focus groups (all of which included a mix of
pediatric and adult practitioners) were conducted—two for epileptologists, two for
neurologists, and one for APNs. Prior to the initiation of each focus group, demographic
data were collected. Each of the three focus groups was moderated by one of the study
investigators. The moderator asked participants questions pertaining to reasons for and for
not discussing SUDEP, and how they discuss SUDEP (see Appendix). Follow-up questions
were asked based on discussion between the participants. Focus groups ranged from 60 to 90
minutes in duration and were audio recorded. Audio recordings were then transcribed
verbatim.
2.3. Data analysis
All transcripts were subjected to conventional content analysis [10]. Sandelowski’s [11]
initial steps for the handling of qualitative data were used as a starting point for analysis.
Data were analyzed per each provider group, and codes were generated; codes were
organized according to main questions asked and discussed during the focus groups. Next,
comparisons of codes were made across groups. Data from all groups were then organized
via themes in order to fulfill the purpose of the study.
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3. Results
3.1. Sample
A total of 43 providers, including 19 epileptologists, 16 neurologists, and 8 APNs,
participated. Of the epileptologists and neurologists, eight were female, and all of the APNs
were female. While we did not collect extensive demographic data, the west coast, east
coast, and central areas of the United States were all represented, and only four participants
had fewer than five years of experience.
3.1. Themes
Themes were generated for the following areas of interest: reasons for discussing SUDEP
(five themes), reasons for not discussing SUDEP (three themes), and ways in which SUDEP
should be discussed (three themes).
3.1.1. Reasons for discussing SUDEP—Across all disciplines, reasons for discussing
SUDEP included: Practical Accountability, Moral Accountability, Proactivity, and
Reactivity. For nurses only, an additional reason was Patient Advocacy.
3.1.1.1. Practical Accountability: Practical accountability refers to a provider offering
patients and family members accurate SUDEP information to facilitate informed decision-
making. All three types of providers stated that they sometimes discuss SUDEP with
patients or family members due to feeling practically accountable to them. The following
selections from answers to questions and general discussion in the focus groups illustrate
practical accountability.
1. “We talk about things like accidents that can occur, injuries that can occur, not
driving, fatalities that can result from driving. I think SUDEP should be just part of
that practical discussion.” (Epileptologist)
2. “We inform every one of them that there are possibilities of complications that
might include sudden death, with or without an accompanying seizure…so they
have that information to base decisions on.” (Neurologist)
3. “You talk about well, you’re already concerned and nervous about this when you
react to—about SUDEP. You are already worried so let’s talk about what you can
do. What can you do to try to prevent this. Give them some information to use.”
(APN)
3.1.1.2. Moral Accountability: Moral accountability refers to discussing SUDEP with
patients and family members in order to avoid withholding important, epilepsy-related
information. Once again, all types of providers reported feeling a moral obligation to
provide patients or their family members with information about SUDEP.
1. “If we don’t share, as a physician that you know—kind of you’re taking
responsibility.” (Epileptologist)
2. “At some point in time, a conversation has to take place about what the end of life
will be. Don’t want caregivers to spend the rest of their life with guilt if they come
into the nursery one morning and find the child blue and cold.” (Neurologist)
3. “You don’t want to put up fear, but it is something that does have to be discussed…
or we aren’t doing our jobs.” (APN)
3.1.1.3. Proactivity: Proactivity refers to provider-initiated discussion of SUDEP to ensure
that patients and family members receive accurate information about SUDEP, and to act as a
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filter against inaccurate information that patients or family might encounter elsewhere. All
providers reported discussing SUDEP for this reason.
1. “I’ve moved toward trying in the first visit, or one of the first visits, because
actually one of my concerns is that the educated patients are gonna go read about it
somewhere else, and be upset that they hadn’t had the discussion.” (Epileptologist)
2. “I would do it early on, rather than them finding it on the Internet, and then coming
in talking to me.” (Neurologist)
3. “I think preventative it’s an important discussion to have and approaching it from a
safety standpoint.” (APN)
3.1.1.4. Reactivity: Reactivity refers to a discussion of SUDEP triggered by a patient’s
behavior—noncompliance, a patient leaving home for the first time, for example. Members
of all three provider groups reported discussions during which they would bring up SUDEP
only after a patient did or was about to do something that the provider felt put the patient at
higher risk of SUDEP.
1. “I only discuss it in those settings where I felt that people weren’t being
compliant.” (Epileptologist)
2. “I’m not comfortable with every family to discuss [SUDEP]. I’d rather put it as a—
I would say as a weapon when they are not agreeing with the medications.”
(Epileptologist)
3. “Generally, I don’t talk…about it unless—the older patients are really
noncompliant with medications. I tend to worry about them and start talking to
them about all the possibilities.” (Neurologist)
4. “I make sure that any of my kids who are teenagers are going away to college—that
I have that discussion…they’re not under the parents’ vigilant eyes.” (APN)
3.1.1.5. Patient Advocacy: The APNs in the sample were the only group to report that they
discuss SUDEP as patient advocates. That is, they feel that patients and family members
have a right and a need to know about SUDEP and will initiate the discussion to promote the
best interest of the patient or family.
1. “What’ll happen is I’ll be bringing it up with a patient that seems appropriate…a
lot of times these patients will’ve been seen by our neurology division for a long
time and no one’s ever brought it up…they’ll say ‘Well, I’ve been seeing doctor so-
and-so and no one’s ever mentioned this as a possibility.’” (APN).
2. “I think there are ways of talking about it. I mean, after all we talk about not
driving and the risks of driving with epilepsy. We seem much more comfortable
talking about the risk of driving with uncontrolled seizures than we do about the
risks of the disease itself.” (APN).
3. “[I discuss it] to have parents recognize that this can happen and precautions need
to be taken.” (APN).
3.1.2. Reasons for not discussing SUDEP—In terms of when not to discuss SUDEP,
for all types of providers involved, and especially the physicians, the theme Not at First
emerged. Additional themes that emerged for this question included, in the case of
neurologists and epileptologists, Moral Accountability and Out of Options.
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3.1.2.1. Not at First: Members of all three provider groups indicated that, in some cases,
they find it best to wait to discuss SUDEP with patients and families until a rapport has been
established.
1. “For me, to talk about it at that first appointment, and it mostly has to do with
practice style. That’s an encounter where the patient’s meeting you for the first
time. They want to feel that they’re going to be better. They want to feel that they
can trust the doctor in terms of making them better.” (Epileptologist)
2. “Sometimes parents or even patients from the first time, they ask you"Is my child
going to die from this?” We have to discuss it at that point, but I’m not sure if we
need really to scare them from the first time we meet them.” (Neurologist)
3. “It’s not always good to scare them right away in the middle of this huge
diagnosis.” (APN)
3.1.2.2. Moral Accountability: Both epileptologists and neurologists cited moral
accountability as a reason not to discuss SUDEP (just as they, along with APNs, also cited
such accountability as a reason to discuss SUDEP). Physicians explained that they
sometimes choose not to discuss SUDEP with patients and family because they feel it is
morally wrong to give information about a complication that is poorly understood and
difficult to prevent.
1. “In the case of SUDEP, to alarm somebody unnecessarily is concerning. If there’s a
purpose—if you can benefit the patient then that’s a different matter. I think that to
me the key is how will this benefit the patient versus unnecessarily alarming the
patient and the family and alerting them to something that we really can’t do
anything about.” (Epileptologist).
2. “You have to consider will this just serve to make them more anxious, or can it
actually help?” (Neurologist)
3.1.2.3. Out of Options: Both physician groups indicated that they often choose not to
discuss SUDEP when all epilepsy treatment options have been attempted and have failed.
1. “I have patients who are – I don’t have anything else to offer them, and I know that
they are at risk, and I know they’re very anxious about everything in life, and often
sometimes a little bit simple. I don’t see the point in giving them something else.
There’s nothing they can do about it. I do feel conflicted about that, and may
change my practices, but it’s very hard.” (Epileptologist)
2. “When there is no response to treatment and nowhere else to go, if it is very severe,
I don’t always discuss [SUDEP].” (Neurologist)
3.1.3. Ways in which to discuss SUDEP—Ways in which SUDEP is discussed
included, in all provider groups, Discussion and Written Materials. In addition, prevalent in
all groups was the finding that procedures for discussing SUDEP with patients and families
need to be somewhat standardized, though the discussion should always be tailored to fit the
patient’s context. As well, all three types of providers expressed the idea that more
informative written materials regarding SUDEP should be developed.
3.1.3.1. Discussion: Providers from all three groups indicated that they frequently use a
face-to-face unscripted format for SUDEP discussions.
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1. “When it comes up [in clinic] it’s not a very long conversation but as I’m talking
about other things I mention it and that I don’t exactly know how their epilepsy is
going to progress but we talk about consequences.” (Epileptologist)
2. “In my experience it just comes up sometimes in the clinic, and I answer
questions.” (Neurologist)
3. “We sit down and we talk with them and answer questions right there.” (APN)
3.1.3.2. Written Materials: Members of both physician groups, as well as APNs, report
providing patients and family members with written informational materials pertaining to
SUDEP. Most reported providing patients and families with materials developed by the
Epilepsy Foundation.
1. “The Epilepsy Foundation has educational materials, and we give patients access to
those.” (Epileptologist)
2. “We typically use the [Epilepsy Foundation] materials as handouts after the
discussion.” (Neurologist)
3. “Often times we provide them with education pamphlets from [The Epilepsy
Foundation].” (APN)
3.1.3.3. Standardization: All three types of providers felt that the process for discussing
SUDEP with patients and family members should be somewhat standardized. However, they
also indicated that SUDEP discussions should be tailored to patients’ and families’ needs. In
addition, all three groups were somewhat unsatisfied with current SUDEP educational
materials available for distribution to patients and family members, and felt that a need
exists for the development of more appealing and accurate SUDEP materials.
1. “So you give them the pamphlet…which is in my mind, is the low level. They’ll
look at it; they’ll toss it; they’ll lose it…there needs to be some improvements
made to the materials, and they should be standardized.” (Epileptologist)
2. “I think we all do different things, what we are comfortable with. As a profession
we probably need more guidance in terms of exactly what to cover, and maybe
how. But you always have to consider that person’s situation…their anxiety, their
risk, all that.” (Neurologist)
3. “What we have to offer them might not be helpful to everyone…it would be good
to revisit those materials and improve them.” (APN)
4. Discussion
Our focus groups of providers caring for epilepsy patients revealed that their decisions about
discussing SUDEP with patients and families were strongly influenced by personal views
that can be understood in the context of thematic approaches. The key elements of those
who discuss SUDEP included practical and moral accountability, proactivity and reactivity
to patient decisions about self-management, and advocacy (APN only). The key elements in
decisions not to discuss SUDEP included a delay in the conversation until the patient-
provider relationship and trust is established and moral accountability of avoiding harm if
there is little or no perceived benefit to having the discussion. Practical and moral
accountability described the providers’ rationale for discussion, whereas proactive and
reactive discussions were meant to affect certain behaviors. Providers made decisions about
SUDEP discussion based on what they believed would be best for the patient.
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While all of the providers reported having given thought to discussing SUDEP with their
patients, many reported being reticent to initiate such a discussion. The vast majority of
patients want information about SUDEP from their neurologists and epileptologists [8]. Yet,
in many cases, these practitioners do not routinely, and in some cases, rarely, discuss
SUDEP [12]. The consequence of providers’ hesitance to discuss SUDEP is that patients
and their family members are uninformed about the possibility of sudden death due to
epilepsy, whether from SUDEP or other causes of epilepsy-related mortality (eg., status
epilepticus, accident, drowning, suicide). For example, several medical examiners told us
that they avoid SUDEP on death certificates since they have occasionally had families who
are adamant that their neurologists told them that seizures are never fatal (O. Devinsky,
personal communication, June, 2013). The gap between what patients want to know and
what information neurologists, epileptologists, and APNs will routinely provide is
significant. The decision-making strategies of the providers in this study, while extremely
well-intended, were not necessarily patient-centered. They did not involve patients in the
decision-making process. This study highlighted key thematic issues that help account for
this gap and suggests approaches to help narrow it.
Perhaps the most effective way to encourage providers caring for epilepsy patients to more
fully discuss epilepsy-related injuries and mortalities, including SUDEP, is to build on the
existing foundation. Since all providers seek to improve their patients’ health through
education, accurate diagnosis and effective therapy, SUDEP education should be a
component of epilepsy care.
Practitioners should more actively include patients in the decision-making process and
provide patients with the necessary information to make sound decisions about their own
care (13). This study’s themes of practical and moral accountability partly address patient-
centered care since providers recognize the importance of providing information about
SUDEP. Yet those themes also inhibited practitioners from talking to their patients about
SUDEP if they believed that informing patients might do harm. All providers should be
educated about the importance of informing patients and families about SUDEP targeting
these thematic issues and including a more patient-centered approach. SUDEP should be
part of basic epilepsy education and care (practical accountability). Educating patients about
SUDEP may reduce the morbidity and mortality of epilepsy by improving compliance,
modification of lifestyle factors and other safety measures by providing information upon
which patients can make self-management decisions. It is ethical care to improve the
potential health outcomes (moral accountability). Accurate information can help prevent
unnecessary fears among many patients and families and replace misinformation from
unreliable sources (proactivity). While reactivity is a common strategy and often triggered
by a breakthrough seizure or patient admitting to a period of nonadherence or unhealthy
lifestyle choices (e.g., sleep deprivation, excess alcohol), education should be employed to
prevent these events. However, a breakthrough seizure or change in lifestyle that increases
seizures may be an opportunity to inform patients about the importance of seizure freedom.
Patients and families want to know about SUDEP and should be informed (advocacy).
This study provided an initial description of health care providers’ practices in SUDEP
discussion. We were able to identify thematic approaches to SUDEP discussion and specific
reasons for why health care providers do or do not talk about SUDEP. Our goal is to help
providers become adept at initiating this difficult discussion with patients, thus building a
partnership to enhance epilepsy management. Because health care providers clearly believe
it is their practical and moral responsibility and want to be proactive in helping patients to
achieve their goals and advocate for patients, the next step is to provide a practical guide to a
discussion of SUDEP. Potential limitations to the generalizability of findings from this study
include a lack of care providers from outside the United States, and that care providers who
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chose to participate in the study may be significantly different (in terms of SUDEP-
discussing practices) from those who elected not to take part.
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Appendix
Question Guide used in Focus Groups*
a. Do you discuss SUDEP with all of your patients and their families? Why or why
not?
b. When you do discuss SUDEP with patients or families, how do you structure that
discussion?
c. When you do discuss SUDEP, what content or information do you include?
d. When do you feel it is most important to discuss SUDEP? When is it least
important?
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e. How do you think practitioners should approach SUDEP discussion with patients
and their family members?
f. Do you feel that your patients and their families want to know about SUDEP? Why
or why not?
*These questions were used as a starting point for each focus group. Questions were added
based on participants’ responses to initial questions and dialogue with each other.
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Highlights
• We examine SUDEP-discussing practices of epilepsy providers.
• Provider decisions about discussing SUDEP are influenced by personal views.
• Key themes are moral/practical accountability and reactivity/proactivity.
• A practical, patient-centered guide to the discussion of SUDEP is needed.
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